Lilly Rises as Study Shows Diabetes Drug Cuts Heart Attack Risk

Stopping these is a long-elusive aim for the tens of millions of diabetes sufferers and their docs, and one analyst who’s additionally a educated doctor even referred to as Thursday’s information of a attainable groundbreaking advance a “holy grail”. Eli Lilly reported positive top-line results for Jardiance, reporting that the EMPA-REG outcome trial met its primary endpoint and demonstrated superiority of Jardiance in CV risk reduction.

Jardiance is part of a newer class of diabetes drugs called SGLT-2 inhibitors, which work by making the kidneys extract a significant amount of sugar from the blood to be excreted in urine. That is the most common form of diabetes, which is closely linked to obesity.

Eli Lilly and partner Boehringer Ingelheim conducted a three year study with almost 7,000 patients.

“This could be important to patient care, but I think we should wait until the medical community digests” all the data, cautioned Dr. Thomas Seck, Boehringer Ingelheim’s U.S. head of drug testing and medical affairs for metabolic disorders, which include diabetes.

Lilly and BI will release full results of the EMPA-REG OUTCOME study on September 17 at the European Association for the Study of Diabetes, which will be held in Stockholm.

“This is a positive, and a first for the field of diabetes”, Sanford Bernstein analyst Tim Anderson said in a research note. Standard of care consisted of glucose-lowering agents and cardiovascular drugs, including antihypertensive and lipid-lowering agents.

Jardiance is a once-daily pill taken in the morning, used along with diet and exercise, to lower blood sugar in adults with type 2 diabetes.

Invokana now leads the SGLT2 inhibitor category with sales of $568m in the first half of the year, while Forxiga brought in $205m for AZ.

Safety of Jardiance was consistent with results of previous trials.

They said while insulin and some medications help control blood sugar levels and sometimes weight, none have been shown to reduce cardiovascular complications. Patients in the trial were getting other drugs to control their diabetes.

In the meantime, Sort 2 diabetes particularly has develop into rather more widespread, together with the weight problems epidemic.

Advertisement

Eli Lilly and Firm (NYSE:LLY) [Trend Analysis] following opening at $86.75 hit its intraday high price of $88.95 moreover then finished at $87.33 as shares moving up 4.25%.